Key Highlights: CEPHEUS Trial SubQ Dara-VRd vs VRd in Transplant-Eligible or Transplant-Deferred NDMM
Panelists discuss how the CEPHEUS study comparing subcutaneous daratumumab plus VRd vs VRd alone in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) provides important insights into the role of quadruplet therapy in this specific population.
Video content above is prompted by the following:
- Let’s transition to patients with NDMM who are considered transplant ineligible or transplant deferred.
- Can you summarize the recent data from the CEPHEUS study evaluating subcutaneous daratumumab plus VRd vs VRd in transplant-ineligible NDMM?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
